SDC1 and Miyoshi myopathy: This bispecific T cell engager (BiTE) can target immune T and NK cells as well as MM cell co-cultures and showed stronger anti-tumor activity in vitro than the combination of single anti-CD138 and anti-CD3 mAbs.